Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Intravenous immunoglobulin Stories

2012-03-27 11:54:22

Intravenous immune globulin (IVIg) is an effective treatment for certain disorders of the nerve and muscles, including Guillain-Barré syndrome (GBS) and a form of neuropathy called chronic inflammatory demyelinating polyneuropathy (CIDP), according to a guideline issued by the American Academy of Neurology. The guideline is published in the March 27, 2012, print issue of Neurology®, the medical journal of the American Academy of Neurology. IVIg is a type of immunotherapy...

2012-03-26 06:30:01

CHARLOTTE, N.C., March 26, 2012 /PRNewswire/ -- CSL Behring has announced that the first patient has been enrolled in the PATH study, an international clinical trial designed to evaluate the efficacy, safety, and tolerability of two different doses of subcutaneous immunoglobulin (SCIg), compared with placebo, in maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). In PATH (Polyneuropathy And Treatment with Hizentra), patients stabilized on intravenous...

2012-03-24 04:50:25

NIH immune-based treatment study underway Criteria for a broadened syndrome of acute onset obsessive compulsive disorder (OCD) have been proposed by a National Institutes of Health scientist and her colleagues. The syndrome, Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), includes children and teens that suddenly develop on-again/off-again OCD symptoms or abnormal eating behaviors, along with other psychiatric symptoms — without any known cause. PANS expands on Pediatric...

2012-03-04 08:45:00

KING OF PRUSSIA, Pa., March 4, 2012 /PRNewswire/ -- Data presented by CSL Behring today suggest that the bioavailability of immunoglobulin G (IgG) therapies is consistent when patients with primary immunodeficiencies switch from one IgG product to another by the subcutaneous route. The analysis, which was presented at the 2012 American Academy of Allergy, Asthma and Immunology annual meeting, was a joint effort between CSL Behring and physicians at University Hospital of Wales, Cardiff, UK...

2011-12-16 08:00:00

The Science Magazine EurekaMag.com publishes articles in all areas of biological science. The latest articles cover Chromatin which is is the combination of DNA and proteins that define the contents of a cell nucleus, IVIG which is a blood product containing the pooled IgG (immunoglobulin antibody G) extracted from blood plasma. The article on Mukoviszidose covers cystic fibrosis which is a genetic disease affecting the lungs, pancreas, liver and intestine. Mannheim, Germany (PRWEB) December...

2011-11-04 12:11:00

HOBOKEN, N.J., Nov. 4, 2011 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) yesterday cleared the way for the U.S. market return of octagam® [Immune Globulin Intravenous (human) 5% Liquid Preparation], the Octapharma USA product used to treat disorders of the immune system. In August 2010, Octapharma initiated a voluntary market withdrawal of selected lots of octagam® 5% in the U.S. in response to an observed increase in thromboembolic...

2011-09-06 09:00:00

TOWSON, Md., Sept. 6, 2011 /PRNewswire/ -- The Immune Deficiency Foundation (IDF) announced today the availability of a free accredited online continuing education (CE) course for nurses. The goal of this CE course is to increase the knowledge of nurses by providing an educational update on primary immunodeficiency disease and immunoglobulin therapy. The IDF is the national patient organization dedicated to improving the diagnosis, treatment and quality of life of persons with primary...

2011-09-02 12:16:56

Drug targets specific defect causing WHIM Syndrome WHAT: A new study reports that a drug already approved by the Food and Drug Administration for use in patients undergoing a bone marrow transplant may also have promise for treating people who have a rare immune deficiency known as WHIM syndrome. People with the syndrome are more susceptible to potentially life-threatening bacterial and viral infections, particularly human papillomavirus infections, which cause skin and genital warts and...

2011-07-28 12:31:34

Female patients make up most of those who could benefit Hard-to-match kidney transplant candidates who receive a treatment designed to make their bodies more accepting of incompatible organs are twice as likely to survive eight years after transplant surgery as those who stay on dialysis for years awaiting compatible organs, new Johns Hopkins research finds. "The results of this study should be a game changer for health care decision makers, including insurance companies, Medicare and...

2011-07-28 07:22:03

(Ivanhoe Newswire) -- A new treatment for hard-to-match kidney transplant patients is providing dramatic survival benefits. According to the study, hard-to-match transplant candidates who receive a new treatment designed to make their bodies more accepting of incompatible organs are twice as likely to survive eight years after transplant surgery as those who stay on dialysis for years waiting for compatible organs. It's estimated that there is more than 20,000 hard-to-match transplant...